Charter Oak Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Charter Oak Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-458	Closed	-$34K	–	906
2022 Q2	$34K	Sell	458 -14	-3%	-$1.05K	﹤0.01%	391
2022 Q1	$42K	Sell	472 -220	-32%	-$20.3K	0.01%	385
2021 Q4	$77K	Hold	692	–	–	0.01%	287
2021 Q3	$87K	Sell	692 -6	-0.9%	-$773	0.01%	265
2021 Q2	$95K	Buy	698 +37	+6%	+$4.87K	0.01%	248
2021 Q1	$90K	Buy	661 +262	+66%	+$39.2K	0.01%	249
2020 Q4	$56K	Buy	+399	New	+$51.1K	0.01%	282

Other funds holding XBI

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Charter Oak Capital Management's XBI Position: Q3 2022 in Review

Charter Oak Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2022, closing a stake of 458 shares — an estimated $34K sold.

Charter Oak Capital Management first reported a position in XBI in Q4 2020 and held it in 7 quarters. The position peaked at $95K in Q2 2021. 704 funds tracked by Wall St. Rank hold XBI as of Q3 2022.

Charter Oak Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2022 after selling out during the quarter.
Charter Oak Capital Management sold 458 State Street SPDR S&P Biotech ETF shares in Q3 2022, an estimated $34K.
Charter Oak Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2020 and held it in 7 quarters.
Charter Oak Capital Management's State Street SPDR S&P Biotech ETF position peaked at $95K in Q2 2021.
704 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2022.

Based on Charter Oak Capital Management's 13F filing for Q3 2022, filed 6 Dec 2022.